TherapeuticsMD, Inc. announced that it received approval to begin screening and enrolling subjects at its fiftieth site, the University of Florida College of Medicine, in the Company's REPLENISH Trial, a phase 3, double-blind, placebo-controlled clinical trial designed to measure the safety and effectiveness of TX 12-001HR, the Company's bio-identical combination 17ß-estradiol and progesterone drug candidate, in treating the symptoms of menopause.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.801 USD | -3.69% | +2.91% | -19.96% |
05-10 | TherapeuticsMD, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-10 | TherapeuticsMD, Inc. Continues Evaluation of Strategic Alternatives | CI |
1st Jan change | Capi. | |
---|---|---|
-19.96% | 20.77M | |
+33.71% | 10.71B | |
+40.41% | 5.23B | |
-15.24% | 4.83B | |
+11.62% | 3.49B | |
+26.25% | 2.28B | |
-38.78% | 1.82B | |
-44.54% | 1.73B | |
-0.50% | 1.64B | |
+0.03% | 1.59B |
- Stock Market
- Equities
- TXMD Stock
- News TherapeuticsMD, Inc.
- TherapeuticsMD Receives Approval to Begin Screening and Enrolling Subjects